Alopecia AreataPhase 3BRAVE-AA2NCT03899259
A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata
A Phase 3 study testing Baricitinib in people with Alopecia Areata, run by Eli Lilly and Company at 96 sites in 10 countries.
Trial summary
The reason for this study is to see if baricitinib is safe and effective in adults with severe or very severe alopecia areata (AA). Read more about this study
- Who is it for?
- Ages 18 to 70 years
- Conditions the study is for
- Alopecia Areata
- What is being tested?
- Baricitinib
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 606 participants
- Where
- 96 sitesin 10 countries
- Study dates
- 8 Jul 2019to 19 Nov 2024
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Are at least 18 years and ≤60 years for males (≤70 years of age for females) at the time of informed consent.
- Have severe or very severe AA, as determined by all of the following:
- Current AA episode of more than 6 months' duration and hair loss encompassing ≥50% of the scalp, as measured by SALT (AA-IGA of 3 or 4) at screening and baseline.
- No spontaneous improvement over the past 6 months.
- Current episode of severe or very severe AA of less than 8 years. Note: participants who have severe or very severe AA for ≥8 years may be enrolled if episodes of regrowth, spontaneous or under treatment, have been observed on the affected areas over the past 8 years.
- Male or nonpregnant, nonbreastfeeding female participants.
Who cannot join
- Primarily "diffuse" type of AA.
- Are currently experiencing other forms of alopecia or any other concomitant conditions that would interfere with evaluations of the effect of study medication on AA.
- Previously treated with an oral Janus kinase (JAK) inhibitor and had an inadequate response (for example, absence of significant terminal hair growth after at least 12 weeks of treatment).
Trial locations and contacts
96 sites in 10 countries.
96 sites in 10 countries
United States33 sites
Great Lakes Research Group, Inc.
Bay City, Michigan, 48706
Bexley Dermatology Research
Bexley, Ohio, 43209
Total Skin and Beauty Dermatology Center, PC
Birmingham, Alabama, 35205
Tufts Medical Center
Boston, Massachusetts, 02111
New England Research Associates
Bridgeport, Connecticut, 06606
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27516
Dermatology Specialists of Charlotte
Charlotte, North Carolina, 28211
Clinical Research Institute of Michigan, LLC
Chesterfield, Michigan, 48047
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106
Florida Academic Centers Research and Education, LLC
Coral Gables, Florida, 33134
Velocity Clinical Research, Providence
East Greenwich, Rhode Island, 02818
Hamzavi Dermatology
Fort Gratiot, Michigan, 48059
Center For Dermatology Clinical Research, Inc.
Fremont, California, 94538
Suzanne Bruce and Associates, PA
Houston, Texas, 77056
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana, 46250
Dermatologists of Southwest Ohio
Mason, Ohio, 45040
New Horizon Research Center
Miami, Florida, 33165
Associated Skin Care Specialists
New Brighton, Minnesota, 55112
Virginia Clinical Research, Inc.
Norfolk, Virginia, 23502
Quest Dermatology Research
Northridge, California, 91324
Qualmedica Research, LLC
Owensboro, Kentucky, 42303
Northwest Dermatology Institute
Portland, Oregon, 97210
Oregon Dermatology and Research Center
Portland, Oregon, 97210
M3-Emerging Medical Research
Raleigh, North Carolina, 27612
Dermatology and Skin Cancer Specialists
Rockville, Maryland, 20850
MediSearch Clinical Trials
Saint Joseph, Missouri, 64506
Progressive Clinical Research
San Antonio, Texas, 78213
Kaiser Permanente Hospital
San Francisco, California, 94118
Investigate MD
Scottsdale, Arizona, 85255
The South Bend Clinic Center for Research
South Bend, Indiana, 46617
ForCare Clinical Research
Tampa, Florida, 33613-1244
Joseph J. Schwartz, M.D.
Troy, New York, 12180
Vital Prospects Clinical Research Institute, P.C.
Tulsa, Oklahoma, 74136
China15 sites
Beijing Chao-Yang Hospital, Capital Medical University
Beijing, Beijing Municipality, 100020
Beijing Friendship Hospital Affiliate of Capital University
Beijing, Beijing Municipality, 100050
Peking University Third Hospital
Beijing, Beijing Municipality, 100191
Chinese PLA General Hospital
Beijing, Beijing Municipality, 100853
Xiangya Hospital Central South University
Changsha, Hunan, 410008
Guangdong Province Dermatology Hospital
Guangzhou, Guangdong, 510018
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, 310014
The Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310052
Jiangsu Province Hospital
Nanjing, Jiangsu, 210029
HuaShan Hospital Affiliated To Fudan University
Shanghai, Shanghai Municipality, 200040
Shanghai Skin Disease Hospital
Shanghai, Shanghai Municipality, 200071
First Affiliated Hospital of Shanxi Medical University
Taiyuan, Shanxi, 30001
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, 300052
The Second Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, 710004
Affiliated Hospital of Jiangsu University
Zhenjiang, Jiangsu, 212000
Brazil8 sites
Centro de Pesquisa Sao Lucas
Campinas, São Paulo, 13034-685
Hospital de Clínicas Da Universidade Estadual de Campinas
Campinas, São Paulo, 13083-888
Irmandade da Santa Casa de Misericordia de Porto Alegre
Porto Alegre, Rio Grande do Sul, 90050-170
IDERJ - Instituto de Dermatologia e Estética do Brasil
Rio de Janeiro, Rio de Janeiro, 22470-220
IBPClin - Instituto Brasil de Pesquisa Clínica
Rio de Janeiro, 22241-180
Faculdade de Medicina do ABC
Santo André, São Paulo, 09060-870
IPITEC
São Paulo, 01223-001
Servidor Público Estadual - IAMSPE - centro de estudos urológicos
São Paulo, 04039-901
Japan8 sites
Juntendo University Hospital
Bunkyo-ku, Tokyo, 113-8431
Hamamatsu University Hospital
Hamamatsu, Shizuoka, 431-3192
Juntendo Tokyo Koto Geriatric Medical Center
Koto-ku, Tokyo, 136-0075
Kyorin University Hospital
Mitaka, Tokyo, 181-8611
Osaka City University Hospital
Osaka, 545-8586
Tokyo Medical Univ. Hospital
Shinjuku-ku, Tokyo, 160-0023
Yamaguchi University Hospital
Ube, Yamaguchi, 755-8505
Yokohama Rosai Hospital
Yokohama, Kanagawa, 222-0036
Argentina7 sites
Buenos Aires Skin
Buenos Aires, Buenos Aires F.D., 1055
Fundacion Respirar
Buenos Aires, Ciudad Autonoma Buenos Aires, C1426ABO
Stat Research
CABA, Buenos Aires, C1023AAB
Instituto de Neumonología y Dermatología
Capital Federal, Buenos Aires, 1425
Centro de Investigaciones Metabólicas (CINME)
Ciudad Autónoma de Buenos Aires, Buenos Aires, 1027
Parra Dermatología
Mendoza, 5500
Centro de Investigaciones Médicas Tucuman
SAN M. de Tucuman, Tucumán Province, T4000AXL
Australia7 sites
Clinical Trials SA Pty Ltd
Campbelltown, South Australia, 5073
Skin Health Institute Inc.
Carlton, Victoria, 3053
Fremantle Dermatology
Fremantle, Western Australia, 6160
Sinclair Dermatology
Melbourne, Victoria, 3002
Woden Dermatology
Phillip, Australian Capital Territory, 2606
Skin & Cancer Foundation Australia
Westmead, New South Wales, 2045
Veracity Clinical Research Pty Ltd
Woolloongabba, Queensland, 4102
Israel7 sites
Emek Medical Center
Afula, Northern District, 1834111
Soroka Medical Center
Beersheba, Southern District, 8410101
Rambam Medical Center
Haifa, Northern District, 3109601
Hadassah Medical Center
Jerusalem, Jerusalem, 9112001
Rabin Medical Center
Petah Tikva, Central District, 4941492
Sheba Medical Center
Ramat Gan, Central District, 5262100
Sourasky Medical Center
Tel Aviv, Tell Abīb, 6423906
South Korea6 sites
Soonchunhyang University Bucheon Hospital
Bucheon-si, Gyeonggi-do, 14584
Dankook University Hospital
Cheonan, Chungcheongnam-do, 31116
Boramae Medical Center
Dongjak-gu, Seoul-teukbyeolsi [Seoul], 07061
Kyunghee University Hospital at Gangdong
Seoul, Seoul-teukbyeolsi [Seoul], 134-090
Severance Hospital, Yonsei University Health System
Seoul, 03722
Ajou University Hospital
Suwon, Gyeonggi-do, 16499
Taiwan4 sites
Chung Shan Medical University Hospital
Taichung, Taichung, 402
National Cheng Kung University Hospital
Tainan, 704
National Taiwan University Hospital
Taipei, 10002
Chang Gung Medical Foundation-Linkou Branch
Taoyuan, 333
About this study
Official title: A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
The reason for this study is to see if baricitinib is safe and effective in adults with severe or very severe alopecia areata (AA).
- Conditions
- Alopecia Areata
- Being tested
- Baricitinib, Placebo
- Medical subject headings
- Alopecia Areata
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
BaricitinibDrug
Also called LY3009104
Administered orally
PlaceboDrug
Administered orally
| Study group | Role | What they receive |
|---|---|---|
| Placebo | Placebo comparator | Participants received two placebo tablets matched to baricitinib, administered orally once daily (QD) to maintain the blind. Receives: Drug: Placebo |
| 2 mg Baricitinib | Experimental | Participants received one 2 mg Baricitinib tablet administered orally QD, and one placebo tablet administered orally QD to maintain the blind. Receives: Drug: Baricitinib |
| 4 mg Baricitinib | Experimental | Participants received one 4 mg Baricitinib tablet and one placebo tablet administered orally QD to maintain the blind. Receives: Drug: Baricitinib |
| Placebo/ Placebo | Placebo comparator | Participants who received two placebo tablets administered orally QD in Period 1 continue to receive the same placebo in Period 2. Receives: Drug: Placebo |
| Placebo/ 2-mg Baricitinib | Experimental | Participants who received two placebo at Period 1 switched to receive 2 mg Baricitinib dose administered orally QD in Period 2. Receives: Drug: Baricitinib |
| Placebo/ 4-mg Baricitinib | Experimental | Participants who received two placebo at Period 1 switched to receive 4 mg Baricitinib dose administered orally QD in Period 2. Receives: Drug: Baricitinib |
| 2-mg Baricitinib/ 2-mg Baricitinib | Experimental | Participants who received 2 mg Baricitinib at Period 1 continued to receive same 2 mg Baricitinib dose administered orally QD in Period 2. Receives: Drug: Baricitinib |
| 2-mg Baricitinib/ 4-mg Baricitinib | Experimental | Participants who received 2 mg Baricitinib at Period 1 switched to receive 4 mg Baricitinib dose administered orally QD in Period 2. Receives: Drug: Baricitinib |
| 4-mg Baricitinib/ Placebo | Experimental | Participants who received 4 mg Baricitinib at Period 1 switched to receive Placebo administered orally QD in Period 2. Receives: Drug: Placebo |
| 4-mg Baricitinib/ 2-mg Baricitinib | Experimental | Participants who received 4 mg Baricitinib at Period 1 switched to receive 2 mg Baricitinib administered orally QD in Period 2. Receives: Drug: Baricitinib |
| 4-mg Baricitinib/ 4-mg Baricitinib | Experimental | Participants who received 4 mg Baricitinib at Period 1 continued to receive same 4 mg Baricitinib administered orally QD in Period 2. Receives: Drug: Baricitinib |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Participants Achieving Severity of Alopecia Tool (SALT) ≤ 20
The SALT uses a visual aid showing the division of the scalp hair into 4 areas with the top of the head constituting 40% of total surface, the posterior/back of head 24%, right side and left side of head 18% each. The percentage of hair loss in each area is determined and is multiplied by the percentage of scalp covered by that area. The total sum of the 4 products of each area will give the SALT score, as developed by the National Alopecia Areata Foundation Working Committee. Only terminal hair is included in the SALT; vellus hair or any fine downy hair is not taken into account in the SALT scoring process. The SALT score will range from 0% to 100%, with lower score indicating better health outcomes.
Measured: Week 36
Secondary outcomes (13)
Percent Change From Baseline in SALT Score at Week 36
SALT uses a visual aid showing the division of the scalp hair into 4 areas with the top of the head constituting 40% of total surface, the posterior/back of head 24%, right side and left side of head 18% each. The percentage of hair loss in each area is determined and is multiplied by the percentage of scalp covered by that area. The total sum of the 4 products of each area will give the SALT score. Only terminal hair is included in the SALT; vellus hair or any fine downy hair is not taken into account in the SALT scoring process. The SALT score will range from 0% to 100%, with lower score indicating better health outcomes. Least Squares Mean (LSM) was calculated using analysis of covariance (ANCOVA) with geographic region duration of current episode at baseline (< 4 years versus ≥4 years), treatment group, and baseline value in the model.
Measured: Baseline, Week 36
Percentage of Participants Achieving 50% Improvement of Severity of Alopecia Tool (SALT50)
SALT uses a visual aid showing the division of the scalp hair into 4 areas with the top of the head constituting 40% of total surface, the posterior/back of head 24%, right side and left side of head 18% each. The percentage of hair loss in each area is determined and is multiplied by the percentage of scalp covered by that area. The total sum of the 4 products of each area will give the SALT score, as developed by the National Alopecia Areata Foundation Working Committee. Only terminal hair is included in the SALT; vellus hair or any fine downy hair is not taken into account in the SALT scoring process. The SALT score will range from 0% to 100%, with lower score indicating better health outcomes. SALT50 indicates at least a 50 % improvement from baseline in the SALT score.
Measured: Week 12
Percentage of Participants With Patient-Reported Outcome (PRO) for Scalp Hair Assessment Score of 0 or 1 With a ≥2-point Improvement From Baseline Among Participants With a Score of ≥3 at Baseline
PRO is an assessment of the particpant's current extent of scalp involvement. It is comprised of 5 category response options: 0= No missing hair (0% of my scalp is missing hair; I have a full head of hair); 1 = A limited area (1% to 20% of my scalp is missing hair); 2 = A moderate area (21% to 49% of my scalp is missing hair); 3 = A large area (50% to 94% of my scalp is missing hair); and 4 = Nearly all or all (95% to 100% of my scalp is missing hair).
Measured: Week 36
Time for Participants to Achieve SALT ≤ 20 at Week 36.
The SALT uses a visual aid showing the division of the scalp hair into 4 areas with the top of the head constituting 40% of total surface, the posterior/back of head 24%, right side and left side of head 18% each. The percentage of hair loss in each area is determined and is multiplied by the percentage of scalp covered by that area. The total sum of the 4 products of each area will give the SALT score, as developed by the National Alopecia Areata Foundation Working Committee. Only terminal hair is included in the SALT; vellus hair or any fine downy hair is not taken into account in the SALT scoring process. The SALT score will range from 0% to 100%, with lower score indicating better health outcomes. Kaplan-Meier method was used for analysis. Time for participants to achieve salt ≤ 20 at week 36 were reported in this outcome measure.
Measured: Week 36
Percentage of Participants Achieving Clinician-Reported Outcome (ClinRO) Measure for Eyebrow (EB) Hair Loss 0 or 1 With ≥2-point Improvement From Baseline (Among Participants With ClinRO Measure for EB Hair Loss ≥2 at Baseline)
ClinRO is a clinician reported assessment which measures a participant's EB hair loss. It is comprised of 4 category response options: 0 = EB have full coverage and no areas of hair loss; 1 = There are minimal gaps in EB hair and distribution is even; 2 = There are significant gaps in EB hair or distribution is not even; 3 = No notable EB.
Measured: Week 36
Percentage of Participants Achieving ClinRO Measure for Eyelash (EL) Hair Loss 0 or 1 With ≥2-point Improvement From Baseline (Among Participants With ClinRO Measure for EL Hair Loss ≥2 at Baseline)
ClinRO measure for EL hair loss is comprised of 4 category response options: 0 = The EL form a continuous line along the eyelids on both eyes; 1 = There are minimal gaps and the EL are evenly spaced along the eyelids on both eyes; 2 = There are significant gaps along the eyelids or the EL are not evenly spaced along the eyelids; 3 = No notable EL.
Measured: Week 36
Percentage of Participants Achieving Patient-Reported Outcome (PRO) Measure for EB 0 or 1 With ≥2-point Improvement From Baseline (Among Participants With PRO Measure for EB ≥2 at Baseline)
PRO is an assessment of the participant's current appearance of eyebrows. It is comprised of 4 category response options: 0 = I have full EB on each eye; 1= I have a minimal gap(s) or a minimal amount of thinning in at least 1 of my EB; 2 = I have a large gap(s) or a large amount of thinning in at least 1 of my EB; and 3 = I have no or barely any EB hairs.
Measured: Week 36
Percentage of Participants Achieving PRO Measure for EL 0 or 1 With ≥2-point Improvement From Baseline (Among Participants With PRO Measure EL ≥2 at Baseline)
PRO assessment of the participant's current appearance of EL. It is comprised of 4 category response options: 0 = I have full EL on each eyelid; 1 = I have a minimal gap or minimal gaps along the eyelids; 2 = I have a large gap or large gaps along the eyelids; and 3 = I have no or barely any EL hair.
Measured: Week 36
Change From Baseline in Skindex-16 Alopecia Areata (AA) Symptoms Domain Score
Skindex-16 AA was adapted from Skindex-16 for use among adults with alopecia areata. It examines the degree to which the participant is bothered by alopecia (hair loss) and associated symptoms. It is composed of 16 items grouped under 3 domains: Symptoms (4 items), Emotions (7 items), and Functioning (5 items). The score of each item ranges from 0 (never bothered) to 6 (always bothered). Symptoms domain score is sum of 4 items, range 0 to 24; Emotions domain score is sum of 7 items, range 0 to 42; Functioning score is sum of 5 items, range 0 to 30. Higher scores indicate a greater impact on quality of life.
LS means was calculated using the ANCOVA model with geographic region, duration of current episode at Baseline (<4 years vs. ≥ 4years), treatment group, and baseline value as fixed factors.
Measured: Baseline, Week 36
Change From Baseline in Skindex-16 AA Emotions Domain Score at Week 36
Skindex-16 AA was adapted from Skindex-16 for use among adults with alopecia areata. It examines the degree to which the participant is bothered by alopecia (hair loss) and associated symptoms. It is composed of 16 items grouped under 3 domains: Symptoms (4 items), Emotions (7 items), and Functioning (5 items). The score of each item ranges from 0 (never bothered) to 6 (always bothered). Symptoms domain score is sum of 4 items, range 0 to 24; Emotions domain score is sum of 7 items, range 0 to 42; Functioning score is sum of 5 items, range 0 to 30. Higher scores indicate a greater impact on quality of life.
LS means was calculated using the ANCOVA model with geographic region, duration of current episode at Baseline (<4 years vs. ≥ 4years), treatment group, and baseline value as fixed factors.
Measured: Baseline, Week 36
Change From Baseline in Skindex-16 AA Functioning Domain Score at Week 36
Skindex-16 AA was adapted from Skindex-16 for use among adults with alopecia areata. It examines the degree to which the participant is bothered by alopecia (hair loss) and associated symptoms. It is composed of 16 items grouped under 3 domains: Symptoms (4 items), Emotions (7 items), and Functioning (5 items). The score of each item ranges from 0 (never bothered) to 6 (always bothered). Symptoms domain score is sum of 4 items, range 0 to 24; Emotions domain score is sum of 7 items, range 0 to 42; Functioning score is sum of 5 items, range 0 to 30. Higher scores indicate a greater impact on quality of life.
LS means was calculated using the ANCOVA model with geographic region, duration of current episode at Baseline (<4 years vs. ≥ 4years), treatment group, and baseline value as fixed factors.
Measured: Baseline, Week 36
Mean Change From Baseline in Hospital Anxiety Depression Scale (HADS) Anxiety Score at Week 36
The HADS is a 14-item self-assessment scale that determines the levels of anxiety and depression that a patient is experiencing over the past week. The HADS utilizes a 4-point Likert scale (for example, 0 to 3) for each question and is intended for ages 12 to 65 years. Scores for each domain (anxiety and depression) can range from 0 to 21, with higher scores indicating greater anxiety or depression.
LS mean was calculated using an ANCOVA model which includes geographic region, duration of current episode at baseline (<4 years vs. ≥4 years), treatment group and baseline score as fixed factors.
Measured: Baseline, Week 36
Mean Change From Baseline in HADS Depression Score at Week 36
The HADS is a 14-item self-assessment scale that determines the levels of anxiety and depression that a patient is experiencing over the past week. The HADS utilizes a 4-point Likert scale (for example, 0 to 3) for each question and is intended for ages 12 to 65 years. Scores for each domain (anxiety and depression) can range from 0 to 21, with higher scores indicating greater anxiety or depression.
LS mean was calculated using an ANCOVA model which includes geographic region, duration of current episode at baseline (<4 years vs. ≥4 years), treatment group and baseline score as fixed factors.
Measured: Baseline,Week 36
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Apr 2019
- Study start8 Jul 2019
- Primary completion24 Jan 2021
- Study completion19 Nov 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (9)Papers the sponsor has linked to this study.
- Other trials for Alopecia AreataStudies of the same condition, open and under way.
- More trials run by Eli Lilly and CompanyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 606 participants (actual)
Sponsor and investigators
- Lead sponsor
- Eli Lilly and Company
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Incyte Corporation
- Responsible party
- Sponsor
- Investigators
- Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM -5 PM Eastern time (UTC/GMT - 5 hours, EST), Study director, Eli Lilly and Company
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03899259
- Sponsor's protocol ID
- 16978
- Other IDs
- I4V-MC-JAIR
- Acronym
- BRAVE-AA2
- Status last verified
- Mar 2026
- First submitted
- 1 Apr 2019
- Last updated
- 7 Apr 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Publications
Vleugels RA, Piraccini BM, Mesinkovska N, Mostaghimi A, Shimomura Y, Sontag A, McSwiney F, Somani N, Pandey H, Denning K, King B. Baricitinib Efficacy Through 4 Years in Responders and Safety up to 5 Years in Adults with Severe Alopecia Areata: Final Results from BRAVE-AA1 and BRAVE-AA2. Dermatol Ther (Heidelb). 2026 Oct 2. doi: 10.1007/s13555-026-01886-9. Online ahead of print.
PubMed 42825995King B, Mostaghimi A, Shimomura Y, Piraccini BM, Blume-Peytavi U, Sontag A, Dutronc Y, Denning K, Kolodsick J, Lu X, Srivastava A, Sinclair R. Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment. Am J Clin Dermatol. 2025 Jul;26(4):611-622. doi: 10.1007/s40257-025-00932-0. Epub 2025 Apr 11.
PubMed 40214720Craiglow B, Lee YW, Vano-Galvan S, Egeberg A, Dutronc Y, Durand F, Pierce E, Yu G, Chen YF, Mostaghimi A. Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib. Dermatol Ther (Heidelb). 2024 Jul;14(7):1959-1968. doi: 10.1007/s13555-024-01208-x. Epub 2024 Jun 21.
PubMed 38904749Senna MM, Kwon O, Piraccini BM, Sinclair R, Ball S, Ding Y, Chen YF, Dutronc Y, King B. Clinical Benefits of Baricitinib Therapy According to Scalp Hair Regrowth in Patients with Severe Alopecia Areata. Dermatol Ther (Heidelb). 2023 Dec;13(12):3209-3220. doi: 10.1007/s13555-023-01063-2. Epub 2023 Nov 22.
PubMed 37991697Ko JM, Mayo TT, Bergfeld WF, Dutronc Y, Yu G, Ball SG, Somani N, Craiglow BG. Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata: A Pooled Analysis of the BRAVE-AA1 and BRAVE-AA2 Trials. JAMA Dermatol. 2023 Sep 1;159(9):970-976. doi: 10.1001/jamadermatol.2023.2581.
PubMed 37556146Piraccini BM, Ohyama M, Craiglow B, Bewley A, Ding Y, Chen YF, Dutronc Y, Pierce E, Durand F, Mostaghimi A. Scalp hair regrowth is associated with improvements in health-related quality of life and psychological symptoms in patients with severe alopecia areata: results from two randomized controlled trials. J Dermatolog Treat. 2023 Dec;34(1):2227299. doi: 10.1080/09546634.2023.2227299.
PubMed 37381691Kwon O, Senna MM, Sinclair R, Ito T, Dutronc Y, Lin CY, Yu G, Chiasserini C, McCollam J, Wu WS, King B. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2). Am J Clin Dermatol. 2023 May;24(3):443-451. doi: 10.1007/s40257-023-00764-w. Epub 2023 Mar 1.
PubMed 36855020King B, Mostaghimi A, Shimomura Y, Zlotogorski A, Choi GS, Blume-Peytavi U, Passeron T, Holzwarth K, Dutronc Y, McCollam J, Yang FE, Stanley S, Wu WS, Sinclair R. Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials. Br J Dermatol. 2023 Feb 10;188(2):218-227. doi: 10.1093/bjd/ljac059.
PubMed 36763878King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, Hordinsky M, Dutronc Y, Wu WS, McCollam J, Chiasserini C, Yu G, Stanley S, Holzwarth K, DeLozier AM, Sinclair R; BRAVE-AA Investigators. Two Phase 3 Trials of Baricitinib for Alopecia Areata. N Engl J Med. 2022 May 5;386(18):1687-1699. doi: 10.1056/NEJMoa2110343. Epub 2022 Mar 26.
PubMed 35334197
Study at a glance
From the registry record, last updated by the sponsor on 7 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
- ClinicalTrials.gov ID
- NCT03899259
- Acronym / sponsor ID
- BRAVE-AA2 / 16978
- Conditions
- Alopecia Areata
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 606 participants (actual)
- Lead sponsor
- Eli Lilly and CompanyIndustry (pharma, biotech, devices)
- Collaborators
- Incyte Corporation
- Study start
- 8 Jul 2019 (actual)
- Primary completion
- 24 Jan 2021 (actual)
- Study completion
- 19 Nov 2024 (actual)
- First posted
- 2 Apr 2019 (actual)
- Results
- Posted 14 May 2024
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The reason for this study is to see if baricitinib is safe and effective in adults with severe or very severe alopecia areata (AA).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 11
| Arm | Type | Receives |
|---|---|---|
| Placebo | Placebo comparator | Drug: PlaceboParticipants received two placebo tablets matched to baricitinib, administered orally once daily (QD) to maintain the blind. |
| 2 mg Baricitinib | Experimental | Drug: BaricitinibParticipants received one 2 mg Baricitinib tablet administered orally QD, and one placebo tablet administered orally QD to maintain the blind. |
| 4 mg Baricitinib | Experimental | Drug: BaricitinibParticipants received one 4 mg Baricitinib tablet and one placebo tablet administered orally QD to maintain the blind. |
| Placebo/ Placebo | Placebo comparator | Drug: PlaceboParticipants who received two placebo tablets administered orally QD in Period 1 continue to receive the same placebo in Period 2. |
| Placebo/ 2-mg Baricitinib | Experimental | Drug: BaricitinibParticipants who received two placebo at Period 1 switched to receive 2 mg Baricitinib dose administered orally QD in Period 2. |
| Placebo/ 4-mg Baricitinib | Experimental | Drug: BaricitinibParticipants who received two placebo at Period 1 switched to receive 4 mg Baricitinib dose administered orally QD in Period 2. |
| 2-mg Baricitinib/ 2-mg Baricitinib | Experimental | Drug: BaricitinibParticipants who received 2 mg Baricitinib at Period 1 continued to receive same 2 mg Baricitinib dose administered orally QD in Period 2. |
| 2-mg Baricitinib/ 4-mg Baricitinib | Experimental | Drug: BaricitinibParticipants who received 2 mg Baricitinib at Period 1 switched to receive 4 mg Baricitinib dose administered orally QD in Period 2. |
| 4-mg Baricitinib/ Placebo | Experimental | Drug: PlaceboParticipants who received 4 mg Baricitinib at Period 1 switched to receive Placebo administered orally QD in Period 2. |
| 4-mg Baricitinib/ 2-mg Baricitinib | Experimental | Drug: BaricitinibParticipants who received 4 mg Baricitinib at Period 1 switched to receive 2 mg Baricitinib administered orally QD in Period 2. |
| 4-mg Baricitinib/ 4-mg Baricitinib | Experimental | Drug: BaricitinibParticipants who received 4 mg Baricitinib at Period 1 continued to receive same 4 mg Baricitinib administered orally QD in Period 2. |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Are at least 18 years and ≤60 years for males (≤70 years of age for females) at the time of informed consent.
- Have severe or very severe AA, as determined by all of the following:
- Male or nonpregnant, nonbreastfeeding female participants.
Key exclusion criteria (3 listed)
- Primarily "diffuse" type of AA.
- Are currently experiencing other forms of alopecia or any other concomitant conditions that would interfere with evaluations of the effect of study medication on AA.
- Previously treated with an oral Janus kinase (JAK) inhibitor and had an inadequate response (for example, absence of significant terminal hair growth after at least 12 weeks of treatment).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| BaricitinibAlso: LY3009104Administered orally | Drug | 2 mg Baricitinib, 2-mg Baricitinib/ 2-mg Baricitinib, 2-mg Baricitinib/ 4-mg Baricitinib, 4 mg Baricitinib, 4-mg Baricitinib/ 2-mg Baricitinib, 4-mg Baricitinib/ 4-mg Baricitinib, Placebo/ 2-mg Baricitinib, Placebo/ 4-mg Baricitinib |
| PlaceboAdministered orally | Drug | 4-mg Baricitinib/ Placebo, Placebo, Placebo/ Placebo |
Primary outcome
Percentage of Participants Achieving Severity of Alopecia Tool (SALT) ≤ 20
Time frame: Week 36
The SALT uses a visual aid showing the division of the scalp hair into 4 areas with the top of the head constituting 40% of total surface, the posterior/back of head 24%, right side and left side of head 18% each. The percentage of hair loss in each area is determined and is multiplied by the percentage of scalp covered by that area. The total sum of the 4 products of each area will give the SALT score, as developed by the National Alopecia Areata Foundation Working Committee. Only terminal hair is included in the SALT; vellus hair or any fine downy hair is not taken into account in the SALT scoring process. The SALT score will range from 0% to 100%, with lower score indicating better health outcomes.
13 secondary outcomes
Percent Change From Baseline in SALT Score at Week 36
Time frame: Baseline, Week 36
Percentage of Participants Achieving 50% Improvement of Severity of Alopecia Tool (SALT50)
Time frame: Week 12
Percentage of Participants With Patient-Reported Outcome (PRO) for Scalp Hair Assessment Score of 0 or 1 With a ≥2-point Improvement From Baseline Among Participants With a Score of ≥3 at Baseline
Time frame: Week 36
Time for Participants to Achieve SALT ≤ 20 at Week 36.
Time frame: Week 36
Percentage of Participants Achieving Clinician-Reported Outcome (ClinRO) Measure for Eyebrow (EB) Hair Loss 0 or 1 With ≥2-point Improvement From Baseline (Among Participants With ClinRO Measure for EB Hair Loss ≥2 at Baseline)
Time frame: Week 36
Percentage of Participants Achieving ClinRO Measure for Eyelash (EL) Hair Loss 0 or 1 With ≥2-point Improvement From Baseline (Among Participants With ClinRO Measure for EL Hair Loss ≥2 at Baseline)
Time frame: Week 36
Percentage of Participants Achieving Patient-Reported Outcome (PRO) Measure for EB 0 or 1 With ≥2-point Improvement From Baseline (Among Participants With PRO Measure for EB ≥2 at Baseline)
Time frame: Week 36
Percentage of Participants Achieving PRO Measure for EL 0 or 1 With ≥2-point Improvement From Baseline (Among Participants With PRO Measure EL ≥2 at Baseline)
Time frame: Week 36
Change From Baseline in Skindex-16 Alopecia Areata (AA) Symptoms Domain Score
Time frame: Baseline, Week 36
Change From Baseline in Skindex-16 AA Emotions Domain Score at Week 36
Time frame: Baseline, Week 36
Change From Baseline in Skindex-16 AA Functioning Domain Score at Week 36
Time frame: Baseline, Week 36
Mean Change From Baseline in Hospital Anxiety Depression Scale (HADS) Anxiety Score at Week 36
Time frame: Baseline, Week 36
Mean Change From Baseline in HADS Depression Score at Week 36
Time frame: Baseline,Week 36
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Apr 2026.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 42825995Vleugels RA, Piraccini BM, Mesinkovska N, Mostaghimi A, Shimomura Y, Sontag A, McSwiney F, Somani N, Pandey H, Denning K, King B. Baricitinib Efficacy Through 4 Years in Responders and Safety up to 5 Years in Adults with Severe Alopecia Areata: Final Results from BRAVE-AA1 and BRAVE-AA2. Dermatol Ther (Heidelb). 2026 Oct 2. doi: 10.1007/s13555-026-01886-9. Online ahead of print.
- Derived from this study: PubMed 40214720King B, Mostaghimi A, Shimomura Y, Piraccini BM, Blume-Peytavi U, Sontag A, Dutronc Y, Denning K, Kolodsick J, Lu X, Srivastava A, Sinclair R. Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment. Am J Clin Dermatol. 2025 Jul;26(4):611-622. doi: 10.1007/s40257-025-00932-0. Epub 2025 Apr 11.
- Derived from this study: PubMed 38904749Craiglow B, Lee YW, Vano-Galvan S, Egeberg A, Dutronc Y, Durand F, Pierce E, Yu G, Chen YF, Mostaghimi A. Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib. Dermatol Ther (Heidelb). 2024 Jul;14(7):1959-1968. doi: 10.1007/s13555-024-01208-x. Epub 2024 Jun 21.
- Derived from this study: PubMed 37991697Senna MM, Kwon O, Piraccini BM, Sinclair R, Ball S, Ding Y, Chen YF, Dutronc Y, King B. Clinical Benefits of Baricitinib Therapy According to Scalp Hair Regrowth in Patients with Severe Alopecia Areata. Dermatol Ther (Heidelb). 2023 Dec;13(12):3209-3220. doi: 10.1007/s13555-023-01063-2. Epub 2023 Nov 22.
- Derived from this study: PubMed 37556146Ko JM, Mayo TT, Bergfeld WF, Dutronc Y, Yu G, Ball SG, Somani N, Craiglow BG. Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata: A Pooled Analysis of the BRAVE-AA1 and BRAVE-AA2 Trials. JAMA Dermatol. 2023 Sep 1;159(9):970-976. doi: 10.1001/jamadermatol.2023.2581.
- Derived from this study: PubMed 37381691Piraccini BM, Ohyama M, Craiglow B, Bewley A, Ding Y, Chen YF, Dutronc Y, Pierce E, Durand F, Mostaghimi A. Scalp hair regrowth is associated with improvements in health-related quality of life and psychological symptoms in patients with severe alopecia areata: results from two randomized controlled trials. J Dermatolog Treat. 2023 Dec;34(1):2227299. doi: 10.1080/09546634.2023.2227299.
- Derived from this study: PubMed 36855020Kwon O, Senna MM, Sinclair R, Ito T, Dutronc Y, Lin CY, Yu G, Chiasserini C, McCollam J, Wu WS, King B. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2). Am J Clin Dermatol. 2023 May;24(3):443-451. doi: 10.1007/s40257-023-00764-w. Epub 2023 Mar 1.
- Derived from this study: PubMed 36763878King B, Mostaghimi A, Shimomura Y, Zlotogorski A, Choi GS, Blume-Peytavi U, Passeron T, Holzwarth K, Dutronc Y, McCollam J, Yang FE, Stanley S, Wu WS, Sinclair R. Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials. Br J Dermatol. 2023 Feb 10;188(2):218-227. doi: 10.1093/bjd/ljac059.
- Derived from this study: PubMed 35334197King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, Hordinsky M, Dutronc Y, Wu WS, McCollam J, Chiasserini C, Yu G, Stanley S, Holzwarth K, DeLozier AM, Sinclair R; BRAVE-AA Investigators. Two Phase 3 Trials of Baricitinib for Alopecia Areata. N Engl J Med. 2022 May 5;386(18):1687-1699. doi: 10.1056/NEJMoa2110343. Epub 2022 Mar 26.
- A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia AreataLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Related trials for Alopecia Areata
Active, not recruitingPhase 3
A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata
Severe Alopecia Areata
RecruitingPhase 2
Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata
Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced), Alopecia Areata
Active, not recruitingObservational study
Litfulo Capsules Special Investigation
Alopecia Areata
Active, not recruitingObservational study
Real-World Effectiveness of Ritlecitinib in Alopecia Areata Patients in the US: A Retrospective Analysis Using EHR and Claims Data
Alopecia Areata
Active, not recruitingObservational study
Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib
Alopecia Areata
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM -5 PM Eastern time (UTC/GMT - 5 hours, EST) study director
Eli Lilly and Company
96 sites in 10 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Baricitinib in people with Alopecia Areata, run by Eli Lilly and Company at 96 sites in 10 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 96 sites in United States, China, Brazil, Japan, Argentina and 5 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 14 May 2024). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of Participants Achieving Severity of Alopecia Tool (SALT) ≤ 20 (time frame: Week 36). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03899259, which also lists 9 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Apr 2026.